Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05890586 · ClinicalTrials.gov registry record · Phase 3
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm B (Fluvoxamine)
A Phase 3 study, sponsored by Susanna Naggie, MD.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,331
- Enrollment target
NCT05890586: Completed Phase 3 study, sponsored by Susanna Naggie, MD.
NCT05890586 is a Phase 3 study that has completed, run by Susanna Naggie, MD. The registered enrollment target is 1,331 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05890586, a Phase 3 study, has completed, sponsored by Susanna Naggie, MD.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,331 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19. Participants will receive either study drug or placebo. They will self-report any new or worsening symptoms or medical events they may experience while taking study drug or placebo. This study is intended to be all remote with no in person visits, unless the study team feels it is in the best interest of a participant to see them in person. Prior and current drug arms are listed on clinicaltrials.gov and will be updated with the activation of any new drug arms. Each study arm will also have its own clinicaltrials.gov entry and will include "Pro00107921" in the Unique Protocol ID.
Primary Outcome
Time to sustained recovery was the number of days between receipt of study drug and the third of 3 consecutive days without symptoms. Participants who died, by definition, did not recover regardless of reported symptom freedom. The reported summary is the median survival time.
Interventions
- OTHER Placebo
- DRUG Fluvoxamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,331 participants |
| Start Date | 2021-06-08 |
| Est. Completion | 2022-09-04 |
| Phase | Phase 3 |
What the finished NCT05890586 record still lists
NCT05890586 is an interventional study that assigns participants to a tested intervention. Its 1,331 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05890586 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05890586 about?
NCT05890586 is a clinical study titled "ACTIV-6: COVID-19 Study of Repurposed Medications - Arm B (Fluvoxamine)". The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19. Participants will receive either study drug or placebo. They will self-report any new or worsening symptoms or med...
What is the current status of trial NCT05890586?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,331 participants. The study started on 2021-06-08. Estimated completion is 2022-09-04.
What interventions are being tested in trial NCT05890586?
The interventions under investigation include: Placebo (OTHER), Fluvoxamine (DRUG).
Who is sponsoring clinical trial NCT05890586?
This trial is sponsored by Susanna Naggie, MD, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05890586's enrollment target sits among peer trials
1,331 183rd of 2000 higher than 1,818 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05415761 · 1,332 participants · NA
Comparative Effectiveness of Mobile Health Smoking Cessation Approaches Among Underserved Patients in Primary Care
- NCT05511298 · 1,332 participants
Empowering Students Project
- NCT06934876 · 1,332 participants
Waveform Capnography Compared to Colorimetric Carbon Dioxide Detection During Tracheal Intubation of Critically Ill Adults
- NCT05536011 · 1,329 participants
WAKIX® (Pitolisant) Pregnancy Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI